文献速递糖尿病

微小剂量即用型液态胰高血糖素对成人1型糖尿病运动相关低血糖的预防效果

Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2023-01-01

本研究纳入完成院内训练期的48例成人1型糖尿病患者,其中45例进入12周门诊阶段,随机分为运动前皮下注射150微克胰高血糖素联合基础率降低50%组、安慰剂联合基础率降低50%组及开放标签单用150微克胰高血糖素组。门诊期共795次运动session中,两个胰高血糖素组1级低血糖发生率分别为12%和16%,均低于安慰剂组的39%;各组间血糖在目标范围内时间无显著差异,不良事件相似。

要点

  • 运动前微小剂量胰高血糖素可降低成人1型糖尿病运动相关低血糖发生率。
  • 联合或不联合CSII基础率降低50%均显示低血糖发生率低于安慰剂组。
  • 各组血糖在目标范围内时间及不良事件无显著差异。

核心结论

  • 微小剂量胰高血糖素联合或不联合CSII基础率降低50%可能有助于降低成人1型糖尿病运动相关低血糖发生率。

研究设计与样本

  • 院内训练期采用交叉设计,受试者随机接受运动前皮下注射150微克胰高血糖素(A组)或安慰剂(B组),同时CSII基础率降低50%。
  • 完成训练期的48例中45例进入12周门诊研究阶段,重新随机分为A组、B组或开放标签C组(单用150微克胰高血糖素)。
  • 参与者在真实环境中进行常规中等至高强度有氧运动,持续30至75分钟。

主要发现

  • 门诊期全部运动session(n=795)中,1级低血糖发生率A组12%(P<0.0001)、C组16%(P=0.0032),均低于B组39%。
  • 0至300分钟血糖低于范围、在范围内及高于范围的时间在各治疗组间无显著差异。
  • 运动碳水化合物摄入量胰高血糖素组低于安慰剂组,但未达统计学显著(P=0.12)。
  • 不良事件在各治疗组间相似。

临床怎么用

  • 原文结论指出,微小剂量胰高血糖素联合或不联合CSII基础率降低50%可能有助于降低成人1型糖尿病运动相关低血糖发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine effect of mini-dose, ready-to-use glucagon on incidence of exercise-associated hypoglycemia (EAH) in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: Individuals initially participated in the in-clinic training phase for which they were randomly assigned to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate. Completers were then rerandomly assigned in the 12-week outpatient investigational phase: arm A, B, or open-label C, 150 µg glucagon alone. Participants were to undertake their usual aerobic exercise at moderate to high intensity for 30 to 75 min in real-world settings. Data were analyzed for incidence of level 1 hypoglycemia based on self-monitoring blood glucose and for various secondary and exploratory end points. RESULTS: Of 48 participants who completed the training phase, 45 continued to the outpatient phase. For all exercise sessions in the outpatient phase (n = 795), incidence of level 1 hypoglycemia was lower in both glucagon arms (A, 12% [P < 0.0001]; C, 16% [P = 0.0032]) than in the placebo arm (B, 39%). Times below range, in range, and above range from 0 to 300 min did not significantly differ among treatment arms. Consumed grams of exercise carbohydrates were lower with glucagon use than with placebo use but did not reach statistical significance (P = 0.12). Adverse events were similar among treatment arms. CONCLUSIONS: Mini-dose glucagon with or without 50% reduction in CSII basal delivery rate may help to decrease EAH incidence in adults with type 1 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Aronson R, Riddell MC, Conoscenti V, et al. Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care. 2023. PMID: 36689626. doi:10.2337/dc22-1145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。